Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
A significant majority of people with obesity using tirzepatide report high satisfaction and a willingness to recommend the treatment. However, the findings are based on self-reported data and may not reflect broader experiences.
Where it sits
this study against the rest of the tirzepatide corpusSummary and findings
This study assessed treatment satisfaction and experiences with tirzepatide among people with obesity or overweight (PwO) without type 2 diabetes, as reported by prescribing physicians. Data were collected from 199 PwO and 151 physicians between October 2023 and January 2025. High satisfaction rates were reported, with 84.4% of PwO having at least one obesity-related complication.
Abstract
Background Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated its efficacy in clinical trials; however, real-world evidence on treatment satisfaction and experiences among people with obesity or overweight (PwO) and their prescribing physicians remains limited. This study aimed to assess the real-world clinical characteristics, treatment patterns, and satisfaction with tirzepatide among PwO without type 2 diabetes (T2D) and their prescribing physicians in the United States. Methods This secondary analysis utilized data from a cross-sectional survey of physicians and PwO from October 2023 to April 2024, and from October 2024 to January 2025. Physicians provided data for PwO meeting selection criteria, at data capture/previous body mass index (BMI) ≥30 or ≥27 and < 30 kg/m2 with at least one obesity-related complication (ORC), without T2D, enrolled in a weight management program, and were receiving tirzepatide at the time of data collection. Sociodemographic and clinical characteristics, treatment history, and satisfaction measures were analyzed. Results Data from 151 physicians and 199 PwO without T2D using tirzepatide were included. Most PwO (84.4%) had ≥1 ORC, with hypertension and dyslipidemia being the most prevalent. Over 90% (n = 45/48) of PwO reported likelihood to recommend tirzepatide reflecting high satisfaction and willingness to recommend tirzepatide to others. Physicians reported long-term safety, ease of dosing, and reduced appetite as key reasons for prescribing tirzepatide. Physicians reported that tirzepatide treatment was successful in the majority of people (78.5%) being treated for obesity. Conclusions The data in these surveys reflected that PwO without T2D prescribed tirzepatide had high motivation, adherence, and satisfaction. These findings provide real-world insights into treatment and satisfaction with tirzepatide.